BPR0C305, an orally active microtubule-disrupting anticancer agent

Area of Science:

• Pharmacology
• Molecular Biology
• Oncology

Background:

• BPR0C305 is a novel N-substituted indolyl glyoxylamide with previously reported in-vitro cytotoxic activity.
• The compound exhibits activity against various human cancer cells, including multidrug-resistant sublines expressing P-glycoprotein (P-gp).

Purpose of the Study:

• To investigate the molecular mechanisms underlying the anticancer action of BPR0C305.
• To evaluate the in-vivo antitumor efficacy of BPR0C305 in preclinical models.

Main Methods:

• In-vitro assays to assess cytotoxicity, tubulin polymerization inhibition, microtubule disruption, and cell cycle progression.
• In-vivo studies in mouse models to evaluate oral activity against leukemia and solid tumors.

Main Results:

• BPR0C305 inhibits tubulin polymerization and disrupts cellular microtubule assembly.
• The compound induces cell cycle arrest at the G2/M phase in cancer cells.
• BPR0C305 demonstrates oral anti-leukemia and anti-solid tumor activity in mouse models.

Conclusions:

• BPR0C305 exhibits a clear molecular mechanism of action against cancer cells.
• Pharmacological and pharmacokinetic findings support BPR0C305 as a promising candidate for further preclinical anticancer drug development.